By analyzing existing technical and fundamental indicators between Htg Molecular and Burning, you can compare the effects of market volatilities on both companies' prices and check if they can diversify away market risk if combined in one of your portfolios. You can also utilize pair trading strategies for matching a long position in Burning with a short position in Htg Molecular. Check out our
pair correlation module for more information.
Let's begin by analyzing the assets.
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Htg Molecular has an asset utilization ratio of 21.86 percent. This denotes that the company is making $0.22 for each dollar of assets. An increasing asset utilization means that Htg Molecular Dia is more efficient with each dollar of assets it utilizes for everyday operations.
Investment perspective, in general, refers to a viewpoint or opinion regarding investment opportunity in HTG Molecular. It encompasses the assessment of an investment's potential risks and rewards, and expectations for its
performance over time. Several factors influence the investment perspective on HTG Molecular, including investment goals, risk tolerance, time horizon, market conditions, and research and analysis. Investors have varying goals, such as capital preservation, income generation, or long-term growth. Risk tolerance plays a significant role in shaping an investor's perspective, with some being more risk-averse and others willing to take on higher risks for potential returns.
Watch out for price decline
Please consider monitoring HTG Molecular on a daily basis if you are holding a position in it. HTG Molecular is trading at a penny-stock level, and the possibility of delisting is much higher compared to other delisted stocks. However, just because the stock is trading under one dollar, does not mean it will be marked for deletion.
Most exchanges require public instruments, such as HTG Molecular stock to be traded above the $1 level to remain listed. If HTG Molecular stock price falls below $1 for 30 consecutive trading days, the exchange can delist it. Once the company reaches this point, they will be sent an initial price violation notice directly from an exchange.
How important is HTG Molecular's Liquidity
HTG Molecular
financial leverage refers to using borrowed capital as a funding source to finance HTG Molecular Diagnostics ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. HTG Molecular financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to HTG Molecular's owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of HTG Molecular's financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the
breakdown between HTG Molecular's total debt and its cash.
What is driving HTG Molecular Investor Appetite?
Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include product or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Revenue Breakdown
Now, let's check Htg Molecular revenue. Based on the latest financial disclosure, Htg Molecular Dia reported 8.61
M of revenue. This is 99.89% lower than that of the Healthcare sector and 99.57% lower than that of the
Diagnostics & Research industry. The revenue for all United States stocks is 99.91% higher than that of Htg Molecular. As for Burning Rock we see revenue of 492.24
M, which is 75.16% lower than that of the Diagnostics & Research
| HTGM | 8.61 Million | 0.35 |
| Sector | 1.98 Billion | 79.82 |
| BNR | 492.24 Million | 19.83 |
Our perspective of the new Htg Molecular hike
Coefficient Of Variation just dropped to -536.98, may denote upcoming price decrease.
As of the 29th of March, Htg Molecular retains the
risk adjusted performance of
(0.18), and Market Risk Adjusted Performance of
(0.59). Htg Molecular
technical analysis makes it possible for you to employ
historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices. Simply put, you can use this information to find out if the firm will indeed mirror its model of historical price patterns, or the prices will eventually revert. We were able to analyze and collect data for nineteen
technical drivers for Htg Molecular Dia, which can be compared to its competitors. Please check out
Htg Molecular Dia information ratio, as well as the
relationship between the potential upside and
kurtosis to decide if Htg Molecular is priced fairly, providing market reflects its last-minute price of 1.59 per share. Please also validate Htg Molecular Dia
total risk alpha, which is currently at
(0.91) to confirm the company can sustain itself at a future point.
The Bottom Line
While many other companies in the diagnostics & research industry are either recovering or due for a correction, Htg Molecular may not be as strong as the others in terms of longer-term growth potentials. To sum up, as of the 29th of March 2022, our actual 90 days 'Buy-Sell' recommendation on the company is
Cautious Hold. We believe Htg Molecular is currently
undervalued with
very high probability of bankruptcy for the next two years.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Gabriel Shpitalnik is a Member of Macroaxis Editorial Board. Gabriel is a young entrepreneur and writes predominantly on the business, technology, and finance sector. He likes to analyze different equity instruments across a wide range of industries focusing primarily on consumer products and evolving technologies.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Gabriel Shpitalnik do not own shares of HTG Molecular Diagnostics. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
[email protected]
